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rameter profiles exhibited significant differences between dis-Expression of DNA topoisomerases in chronic proliferative
tinct types of chronic renal disease.kidney disease.
Conclusion. Topoisomerase IIa expression is tightly linkedBackground. Circulating autoantibodies to human topoisom-
to cell cycling, and topoisomerase I is likely a reflection of geneerases have been reported in glomerular kidney disease associ-
transcription. Rapidly progressing glomerular disease there-ated with scleroderma and systemic lupus erythematosus. How-
fore appears to be accompanied by active mesangial cell prolif-ever, limited information is available about the expression of
eration and increased metabolic activity in glomerular cells.topoisomerases in the kidney under normal and pathological
The correlation with inflammatory infiltrates is likely to reflectconditions.
a positive feedback mechanism involving cytokines, growth fac-Methods. The expression of DNA topoisomerases I and IIa
tors, and adhesion molecules. Assessment of topoisomeraseswas studied by immunohistochemistry on archival biopsies from
may therefore be of diagnostic help and might allow prognostic70 patients with chronic renal diseases. Normal kidney tissue
predictions. Provided that our observations are supported bywas examined for comparison. Topoisomerase I was detected
clinicopathological follow-up studies, one might envisage theby means of monoclonal antibody (mAb) C21, and topoisomer-
use of topoisomerase inhibitors in the therapy of chronic prolif-ase IIa was detected by means of mAb Ki-S4. In addition, mAb
erative renal disease refractory to current treatment protocols.Ki-M1p was used to assess the density of monocytic infiltrates.
All parameters were assessed in a semiquantitative manner.
Results. Glomerular topoisomerase IIa levels were increased
in mesangial proliferative glomerulonephritis (MPGN), rapidly The pathogenesis of glomerular kidney diseases is in-
progressive glomerulonephritis (RPGN), and lupus nephritis
completely understood. It nevertheless emerges that in(LN) and were reduced in membranous glomerulonephritis
most instances, antibodies and antigen–antibody com-(MGN), chronic transplant nephropathy (CTN), and tubuloin-
terstitial nephritis (TIN). Tubular epithelia displayed high to- plexes play an essential role in the initiation and perpetu-
poisomerase IIa levels in mesangiocapillary glomerulonephri- ation of the pathologic process [1, 2]. This has notably
tis (MCGN), RPGN, TIN, miscellaneous entities (MISC) and been demonstrated in lupus nephritis (LN) [3–5]. Al-
LN, and displayed low levels in MPGN and CTN. Topoisomer-
though anti-ds-DNA autoantibodies appear to be a ma-ase I expression was high in the glomeruli of focal segmental
jor pathogenetic factor [6–8], various other autoantibod-glomerulosclerosis (FSGS), MCGN, and RPGN and was ex-
treme in LN, whereas it was strikingly diminished in the glomer- ies are found in patients with LN [9]. Among these,
uli of MGN, CTN, and TIN. Almost all conditions displayed antibodies to both topoisomerases I and II have been
lower tubular topoisomerase I levels than normal kidney, except described [10–12]. The mechanisms underlying the gen-
for LN, in which the enzyme content was markedly increased.
eration of antibodies to nuclear proteins remain largelyIncreased glomerular monocytic infiltrates were found in FSGS,
unclear. However, topoisomerases are intimately associ-MCGN, RPGN, TIN, and LN, and tubulointerstitial Ki-M1p1
ated with DNA [13, 14] and might therefore be embracedcells were seen at high numbers in MCGN, RPGN, TIN, MISC,
and LN. The expression of the topoisomerases I and IIa was in the process leading to anti-DNA antibody formation,
significantly correlated; also, topoisomerases showed a positive as suggested by the presence of antihistone antibodies
association with the density of monocytic infiltrates. The pa-
in LN [15]. Since these considerations point to a possible
role of topoisomerases in the autoimmune process, we
investigated the expression of these proteins in differentKey words: glomerulonephritis, cell proliferation, monocytes, inflam-
mation, scleroderma, lupus nephritis, tubulointerstitial nephritis. types of glomerulonephritis and a few other chronic kid-
ney diseases.
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mitotic chromosomes [13]. Topoisomerase I, a 100 kD to be excluded. In 11 cases, no tissue remained after
diagnostic electron microscopy, and an additional 24protein, induces DNA single-strand nicks and is therefore
a central player in the process of transcription [16–18]. biopsies were judged to be inappropriate because of an
insufficient number of preserved glomeruli. SeventyVariable amounts of this protein may be expressed in
proliferating, resting, and terminally differentiated cells, specimens fulfilled the criteria for reliable evaluation
[37]. The majority of the biopsies were taken from pa-but the mechanisms regulating topoisomerase I expres-
sion are largely unknown [19]. Topoisomerase II pre- tients with creatinine levels ,1.5 mg/dL. Only glomeruli
that appeared unaltered or well preserved by conven-sents with two isoforms designated as with respective
molecular masses of 170 and 180 kD. Despite consider- tional morphology were evaluated thoroughly; glomeruli
with advanced change (for example, noticeable necrosisable sequence homologies, the two isozymes assume dif-
ferent physiological functions [20]. The a form is ex- or fibrosis) were disregarded in the evaluation.
The following entities were studied: minimal-changepressed in a cell-cycle–dependent manner [21], cuts and
religates double-stranded DNA, and is involved in DNA disease (MCD; N 5 5), mesangial proliferative glomeru-
lonephritis (MPGN; N 5 9, two cases with predominantreplication [13, 22]. In addition, it is a major constituent
of the chromosomal scaffold indispensable for chromo- IgA deposits), focal segmental glomerulosclerosis (FSGS;
N 5 3), membranous glomerulonephritis (MGN; N 5 9),some condensation and segregation during mitosis [14].
Conversely, little is known about the function of the mesangiocapillary glomerulonephritis (MCGN; N 5 2),
rapidly progressive glomerulonephritis (RPGN; N 5 6,isoform, the expression of which is proliferation indepen-
dent [23], except that it appears to play a role in the 3 cases of Wegener’s granulomatosis and 3 cases of anti-
glomerular basement membrane glomerulonephritis),organization of nucleoli and the transcription of ribo-
somal genes [24]. It has also been speculated that under hydronephrosis (N 5 1), tubulointerstitial nephritis
(TIN; N 5 9), chronic transplant nephropathy (CTN;certain conditions, topoisomerase IIb may assume the
functions of the a isoform and thus compensate, to some N 5 3), LN (N 5 8), and miscellaneous disorders (MISC;
N 5 3) comprising Alport syndrome, benign nephroscl-extent, for possible deficiencies of the latter [25].
It has recently become possible to assess the expression erosis, and unclassified glomerular change. Normal kid-
ney tissue was obtained from 12 tumor nephrectomyof type I and type II topoisomerases in archival histologic
material by means of specific monoclonal antibodies. We specimens by selection of morphologically unaltered ar-
eas. Diagnoses were made by conventional microscopyused antibody C21 directed to topoisomerase I (a gener-
ous gift from Y.-C. Cheng, Yale University, New Haven, (hematoxylin and eosin and periodic acid–Schiff stain-
ing) and, in cases of glomerular disease, were confirmedCT, USA) and an antibody produced in our laboratory,
Ki-S4, which reacts with a fixation-resistant epitope of by immunohistochemistry (IgA, IgG, IgM, C3) and elec-
tron microscopy.topoisomerase IIa [26]. Both antibodies have been thor-
oughly tested in a wide variety of human tissues and
Immunohistochemistrywere found to yield consistent and reproducible results.
In addition, it seemed interesting to correlate the ex- The following primary antibodies were used: Ki-S4
(antitopoisomerase IIa, undiluted cell culture supernatantpression of topoisomerases with the intensity of inflam-
mation. Although immune reactions are essentially me- produced in our laboratory) [26], C21 (antitopoisomerase I,
diluted 1:100, a generous gift from Y.-C. Cheng), anddiated by both B and T lymphocytes [27–29], monocytic
cells appear to be the main effectors of the chronic in- Ki-M1p (anti-CD68, undiluted cell culture supernatant
produced in our laboratory) [36]. Immunohistochemistryflammatory process [30–34]. Therefore, the sections were
stained with monoclonal antibody (mAb) Ki-M1p, which was performed as described [26, 36]. Briefly, 3 to 5 mm
thick sections were cut from the formalin-fixed, paraffin-is a particularly sensitive marker of monocytes and nearly
all of their differentiation forms [35, 36]. embedded samples, mounted on 3-aminopropyl-trieth-
oxy-silane–coated slides and dried for 24 hours at 378C.This study shows that distinctive patterns of topoisom-
erase expression and monocytic infiltrates may be ob- Subsequently, they were dewaxed in xylene and rehy-
drated in graded ethanol. Endogenous peroxidase activ-served in different pathological conditions, and that they
are likely to reflect the typical clinical courses of these ity was blocked with 3% H2O2 in methanol for 30 minutes
at room temperature. Retrieval of nuclear antigens (to-diseases.
poisomerases I and II) required pretreatment of the sec-
tions by moist autoclaving [38] in 0.01 mol citric acid,
METHODS
pH 6.0, for 21⁄2 minutes. To restore the reactivity of the
Biopsies epitope recognized by Ki-M1p, the sections were di-
gested in 0.01% protease for 10 minutes at 378C. TheOne hundred five patients with various kidney diseases
initially entered this study. Paraffin-embedded kidney primary antibodies were then incubated on the slides for
60 minutes at room temperature. For nuclear antigens,biopsies were available in all cases, but a portion had
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the immunoreaction was enhanced using a streptavidin- the significance levels was verified by comparison of the
rank sums according to the method of Tukey and Kramer.biotin complex with peroxidase and rabbit anti-mouse
IgM as secondary antibody (all reagents from Dako, Ham- Statistical significance was thus assumed at P , 0.05.
burg, Germany). Because of the high cytoplasmic peroxi-
dase activity in kidney tissue, Ki-M1p immunostaining
RESULTS
was enhanced by means of the alkaline phosphatase anti-
Topoisomerase IIa was expressed at various levels inalkaline phosphatase (APAAP) technique [39]. The sec-
tubular epithelia and in glomerular interstitial cells thattions were counterstained with Mayers’ hematoxylin.
appeared to be mesangial cells by morphology. Staining
of tubular epithelia often appeared in clusters (Fig. 1A).Evaluation of immunolabeling
A portion of cases displayed a negative reaction in eitherOnly nuclear labeling was accepted as specific for to-
glomeruli or tubuli or both, but false negativity could bepoisomerases. Occasional faint cytoplasmic staining was
excluded because of the presence of single cells withconsidered as a nonspecific cross-reaction, probably be-
unmistakable nuclear reactivity, for example, in inflam-cause of remnants of endogenous peroxidase activity.
matory infiltrates. Endothelial cells were hardly ever la-The fraction of positive cells was evaluated in a semi-
beled except for one case of glomerulosclerosis, in whichquantitative manner for each cell type separately. In
rare glomerular endothelia reactive for topoisomeraseglomeruli, the positive reaction was scored as 1 if the
IIa were found. None of the positive cells could be con-median number of labeled cells ranged between 1 and
fidently identified as podocytes. In the tubulointersti-10% of one cell type (for example, mesangial cells or
tium, positive fibroblasts were encountered at low num-vascular cells), as 11 for a median between 10 and 25%,
bers, and only occasional vascular endothelial cells wereand as 111 for any median value greater than 25%.
reactive. Dense mononuclear infiltrates in TIN usuallyNegativity was recorded in the absence of any staining
contained numerous positive cells. Topoisomerase IIareaction. On account of the higher overall reactivity in
was evaluated only for mesangial cells and tubular epi-the tubular and interstitial compartments, the three cate-
thelia in this study.gories (1, 11, and 111) were defined on the basis
Nearly all cell types, including mesangial cells, glomer-of 1 to 10%, .10 to 50%, and .50% positive cells,
ular endothelia and epithelia, tubular epithelia, and in-respectively.
terstitial cells such as fibroblasts and vascular endotheliaBecause the intensity of Ki-S4 and Ki-M1p immuno-
exhibited topoisomerase I expression. Distal tubuli usu-staining was homogeneous in general, only the absolute
ally displayed higher staining rates than proximal tubuli.number of labeled cells was taken into account. By con-
In contrast to topoisomerase IIa, the distribution of posi-trast, the intensity of topoisomerase I immunostaining
tive cells was diffuse as a rule (Fig. 1B). Interstitial in-showed wide variations between one specimen. We
flammatory infiltrates contained up to 90% strongly la-therefore sought to adjust the scoring for these variations
beled cells, the majority of which were lymphocytes.in order to include the relative protein content in the
Again, only mesangial cells and tubular epithelia wereassessment. This was done by multiplying the number of
considered for evaluation.positive cells by a score assigned to the staining intensity
Ki-M1p–positive cells that were encountered both inranging from 1 (faint staining) to 3 (strong staining), and
glomeruli and the tubular interstitium displayed the typi-subsequently dividing the result by 3 to obtain numbers
cal aspect of blood monocytes or resident macrophagesranging from 0 to 100. These were categorized as de-
with fusiform or plump shapes and small ovoid nucleiscribed previously in this article.
(Fig. 1C). Although they were almost invariably present,
Statistical analysis their density varied widely in our series. Their distribu-
tion was mostly diffuse, but in TIN and LN, occasionalAll calculations were performed using the SPSS soft-
thick clusters of monocytogenic cells were observed. Inware package on a PC computer. The empiric distribu-
addition, tubular epithelia often showed a coarsely gran-tions of the values of individual variables were assessed
ular cytoplasmic staining reflecting a high content of lyso-for the entire series and compared with theoretical distri-
somes. This staining was not considered in the evaluation.butions based on the median by means of the Kolmo-
All variables (topoisomerases I and IIa as well as Ki-gorov-Smirnov test. Correlations between variables were
M1p) were found to be Poisson distributed in both thecomputed by means of linear regression analysis using
glomeruli and the tubular compartment. Glomerular andthe Spearman rank correlation coefficient. Medians and
tubular topoisomerase IIa values perfectly matched theranks of variables between different categories (entities)
Poisson distribution with l 5 0.62, d 5 0.017, P 5 1.0,were compared using the Mann–Whitney U-test and the
and l 5 0.67, d 5 0.033, P 5 1.0, respectively. GlomerularKruskal–Wallis nonparametric analysis of variance. To
topoisomerase I (l 5 1.11, d 5 0.045, P 5 0.26), tubularadjust for multiple comparisons, Bonferroni corrections
were performed on all P values, and the acceptability of topoisomerase I (l 5 1.54, d 5 0.038, P 5 0.54), glomerular
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Table 1. Tendencies in the expression of DNA topoisomerases and MCGN, RPGN, TIN, and MISC; intermediate in MCD,
the relative density of monocytic infiltrates (Mf ) in different types
MGN, and FSGS; and low in MPGN, CTN, and normalof chronic renal disease as compared to the median values (—)
determined in our series kidney.
On average, topoisomerase I was strongly expressedGlomeruli Tubuli
Interstitium in the glomeruli of LN (Fig. 3A) and to a slightly lesser
topIIa topI Mf topIIa topI Mf
extent in MCGN, RPGN, and FSGS; intermediate levels
MCD — — # — — # were found in MCD, MPGN, MISC, and normal kidney,
MPGN " — — # — #
and low levels were found in MGN, CTN, and TIN. InFSGS — " " — — —
MGN # # # — — # the tubular compartment, the average topoisomerase I
MCGN — " "" " # " expression was very high in LN (Fig. 3B); high in normal
RPGN " " "" " — "
kidney; intermediate in MCD, MPGN, FSGS, MGN, andCTN # # # # ## —
TIN # # " " # " RPGN; low in MCGN and TIN; and markedly reduced
MISC — — — " ## " in CTN and MISC.
LN "" "" "" "" "" "
Ki-M1p–positive monocytogenic cells were found inNK # — — # " —
the glomerular interstitium and occasionally within capil-Abbreviations are: top, topoisomerases; MCD, minimal-change disease;
MPGN, mesangioproliferative glomerulonephritis; FSGS, focal segmental glo- lary loops as well as in the interstitium of the tubular
merulosclerosis; MGN, membranous glomerulonephritis; MCGN, mesangio- apparatus. In the glomeruli, their numbers were highestcapillary glomerulonephritis; RPGN, rapidly progressive glomerulonephritis;
CTN, chronic transplant glomerulopathy; TIN, tubulointerstitial nephritis; MISC, in LN, RPGN, and MCGN; moderately high in FSGS
miscellaneous; LN, lupus nephritis; NK, normal kidney; #, reduced; ", moderately and TIN; intermediate in MISC, MPGN, and normalincreased; "", markedly increased.
kidney; and low in MCD, MGN, and CTN. The tubular
interstitium exhibited high numbers of Ki-M1p1 cells
in cases of MCGN, RPGN, TIN (Fig. 3C), MISC, and
(l 5 1.43, d 5 0.04, P 5 0.35) and intertubular Ki-M1p LN; intermediate numbers in FSGS, CTN, and normal
(l 5 1.53, d 5 0.06, P 5 0.21) showed slight divergences kidney; and low numbers in MCD, MPGN, and MGN.
from the values expected from the median, but neverthe- We further examined whether the previously men-
less met the criteria of the Poisson approximation. tioned parameters were able to discriminate between
Considering this distribution pattern, we sought to normal and pathological conditions and between differ-
denote trends by defining parameter values around the ent types of kidney disease. With respect to glomerular
median as intermediate, around and below the theoreti- topoisomerase IIa expression, only LN was significantly
cal 25th percentile as low, around the 75th percentile different from normal kidney (P 5 0.026), whereas tubu-
as high, and around the 90th percentile as extreme lar topoisomerase IIa discriminated between normal kid-
(Table 1). With this approach, the highest average topo- ney and TIN (P 5 0.022) as well as LN (P 5 0.009). The
isomerase IIa expression levels in glomeruli were found level in MISC (P 5 0.043) and RPGN (P 5 0.05) was of
in LN (Fig. 2A). A slightly lesser, but still strong expres- borderline significance. Similarly, only LN significantly
sion was seen in MPGN and RPGN. Cases of MCD, differed from normal kidney in terms of glomerular topo-
MCGN, FSGS, and MISC displayed intermediate levels isomerase I expression (P 5 0.031), but tubular topo-
(Fig. 2B), whereas topoisomerase IIa expression ap- isomerase I expression was not distinctive in any of the
peared to be markedly reduced in MGN, CTN, TIN, entities, except for CTN and MISC, in which its decrease
and normal kidney tissue. In tubular epithelia, average was of borderline significance (P 5 0.052). The intra-
glomerular numbers of Ki-M1p–positive cells were sig-topoisomerase IIa levels were extreme in LN; high in
b
Fig. 1. (left-hand column) (A) Topoisomerase IIa expression in normal kidney. Reactivity (brown nuclei, arrows) is seen in a few tubular epithelia
in a clustered pattern. Glomeruli are negative (3140). (B) Topoisomerase I expression is typically diffuse in normal kidney; numerous tubular
epithelia are labeled, whereas only rare glomerular cells (arrows) show distinct nuclear staining (3350). (C) Normal kidney tissue contains only
a few interstitial histiocytes revealed by faint red cytoplasmic staining (arrows); a nonspecific granular reactivity in tubular epithelia (arrowheads)
is probably due to the presence of lysosomes (3350).
Fig. 3. (right-hand column) (A) Abundant glomerular expression of topoisomerase I in lupus nephritis (3350). (B) Very high levels of topoisomerase
I expression are also found in tubuli, vascular endothelia, and interstitial inflammatory infiltrates (360). (C) The highest density of histiocytic/
monocytic infiltrates in the tubulointerstitium was usually encountered in TIN, with a moderately dense infiltrate in the glomeruli (red label,
3140).
Fig. 2. (bottom) (A) In lupus nephritis (LN), there is a marked increase in both glomerular (arrows) and tubular (arrowheads) topoisomerase
IIa expression (3350). (B) Intermediate expression levels are encountered, for instance, in MCGN (3350; arrows and arrowheads as described
in this article).
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nificantly increased in LN (P 5 0.02) and RPGN (P , kidney disease. Although only a few entities differed
0.005) and decreased in MCD (P 5 0.016), MGN (P 5 significantly from normal kidney tissue, others showed at
0.011), and CTN (P 5 0.011). By contrast, monocytic least a clear trend toward an alteration of topoisomerase
infiltrates in the tubular interstitium were distinctive only protein levels in either glomeruli or tubuli or both. The
in TIN (P 5 0.019). lack of a statistical significance might be explained by
Significant differences concerning glomerular topo- the small sample sizes of some entities, and it is well
isomerase IIa were also observed between LN and MGN conceivable that the tendencies found in this study might
(P 5 0.027) and LN and TIN (P 5 0.043). Tubular achieve statistical significance in larger series.
topoisomerase IIa only distinguished between LN and Glomerular topoisomerase IIa levels were intermedi-
MPGN (P 5 0.034). Glomerular topoisomerase I levels ate or diminished in normal kidney and in diseases known
elicited significant differences between LN and MPGN to progress slowly, such as MCD, MGN, FSGS, and
(P 5 0.02), MGN (P 5 0.016), RPGN (P 5 0.041), and MCGN [40]. Conversely, rapidly evolving disorders such
TIN (P 5 0.006), and between RPGN and TIN (P 5 as RPGN and proliferative LN were consistently associ-
0.039). Also, only LN was distinctive in terms of tubular ated with an increased topoisomerase IIa expression in
topoisomerase I and proved significant in the comparison glomerular interstitial cells. Considering that topoisom-
with MCD (P 5 0.017), MPGN (P 5 0.002), MGN (P 5 erase IIa is essentially cell-cycle-associated [21, 26, 41, 42],
0.016), MCGN (P 5 0.037), RPGN (P 5 0.039), CTN (P 5 this overexpression is likely to reflect a proliferation of
0.014), TIN (P 5 0.005), and MISC (P 5 0.014). mesangial cells. The same is valid for topoisomerase IIa
Glomerular monocytic infiltrates were significantly dif- in tubular epithelia, in which an increased proliferative
ferent between MCD and RPGN (P 5 0.01), TIN (P 5 activity probably mirrors an attempt at regeneration
0.025) and LN (P 5 0.01); the divergence from MCD after tubular damage [43]. Consequently, tubular injury
was of borderline significance (P 5 0.052). Moreover, appears to be of little importance in MCD, MPGN, FSGS,
there were significant differences between MPGN and and MGN, consistent with a predominantly intraglomer-
RPGN (P 5 0.013), as well as LN (P 5 0.016); FSGS ular pathological process. On the other hand, tubular
and MGN (P 5 0.042); MGN and RPGN (P 5 0.002), involvement has been described in entities like MCGN,
TIN (P 5 0.012), and LN (P 5 0.002); RPGN and CTN RPGN, and LN [40, 44], which is well in line with our
(P 5 0.02), as well as MISC (P 5 0.039); and CTN and results. TIN is a disease essentially confined to the tubu-
TIN (P 5 0.027), as well as LN (P 5 0.014). lointerstitium that typically goes along with destruction
With respect to monocytic infiltrates in the tubular of tubular epithelia, which is substantiated by the obser-
interstitium, MCD differed from TIN (P 5 0.021), vation of an augmented topoisomerase IIa expression.
MPGN from TIN (P 5 0.003) and LN (P 5 0.014), and In this context, it is worth noting that active proliferation
MGN from TIN (P 5 0.006) and LN (P 5 0.034). A was mainly found in distal tubuli, suggesting a higher
tendency toward borderline significance appeared be- regenerative capacity compared with the more special-
tween MCD and LN (P 5 0.051), MPGN and RPGN ized proximal tubular epithelium.
(P 5 0.052), and CTN and TIN (P 5 0.052). Topoisomerase I was abundantly expressed in both
Finally, we determined the relationships between the the glomerular interstitium and tubular epithelia in most
parameters of this study. Topoisomerase IIa in the glo- instances. Besides increased protein levels in LN, RPGN,
meruli was significantly correlated to its expression in MCGN, and FSGS, occasional reductions retained our
the tubuli and was weakly correlated to the monocytic attention. In glomeruli, these were encountered in CTN,
infiltrate in glomeruli. There was also a limited associa- MGN, and TIN, whereas tubular epithelia displayed de-
tion of tubular topoisomerase IIa expression with glo- creased levels in MCGN, TIN, CTN, and MISC despite a
merular topoisomerase I and with monocytic infiltrates reasonably high expression in the glomeruli. Surprisingly,
in both glomeruli and the tubular interstitium. Glomeru-
comparatively high levels of tubular topoisomerase I ex-
lar topoisomerase I levels strongly correlated with the
pression were found in normal kidney. This finding is nottubular expression of the enzyme and, to a lesser extent,
easy to interpret. In contrast to topoisomerase IIa, topo-with glomerular monocytic infiltrates. Weak trends to-
isomerase I is not cell cycle-regulated, but because of itsward an association were found between tubular topo-
role in transcription, it is likely to reflect the metabolicisomerase I expression and glomerular monocytic infil-
activity of cells (Kellner et al, manuscript in preparation).trates and between the numbers of monocytogenic cells
Renal cell metabolism therefore appears to be activein glomeruli and tubular interstitium. Regression coeffi-
under physiological conditions, which is in line with earliercients and significance levels are shown in Table 2.
observations [45]. The finding of an increase in glomerular
topoisomerase I levels in some types of glomerulonephri-
DISCUSSION tis might reflect an increased transcription of cytokines
and signal mediators. Intriguingly, many pathologicalWe have shown that characteristic expression patterns
of DNA topoisomerases may exist in different types of changes appear to go along with a reduction of topoisom-
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Table 2. Correlations between the parameters examined in this study
Topoisomerase
Monocytes
IIa glomeruli IIa tubuli I glomeruli I tubuli glomeruli
Topoisomerase IIa tubuli r 5 0.582
P , 0.0005
Topoisomerase I glomeruli r 5 0.281 r 5 0.336
P 5 0.11 P 5 0.045
Topoisomerase I tubuli r 5 0.284 r 5 0.257 r 5 0.764
P 5 0.085 P 5 0.22 P , 0.0005
Monocytes glomeruli r 5 0.328 r 5 0.343 r 5 0.465 r 5 0.256
P 5 0.03 P 5 0.03 P , 0.0005 P 5 0.17
Monocytes tubulointerstitium r 5 0.152 r 5 0.351 r 5 0.061 r 5 0.003 r 5 0.28
P . 0.9 P 5 0.015 P . 0.9 P . 0.9 P 5 0.09
erase I expression, at least in the glomerular compart- and complement activation [46] are likely to trigger the
expression of monocyte chemoattractant proteins, forment, suggesting that these result in quenching of the
metabolic activity. However, with the mechanisms regu- example, monocyte chemoattractant protein-1 (MCP-1)
and granulocyte macrophage colony-stimulating factorlating topoisomerase I expression being poorly under-
stood as yet, these considerations are conjectural. (GM-CSF), by mesangial cells, tubular epithelia, and
possibly also endothelia [47–53]. This entails a migrationOn the other hand, maximum levels of both topoisom-
erases were consistently observed in LN. Besides the of blood monocytes into the interstitium, where they
differentiate to tissue macrophages and secrete cytokinespreviously mentioned considerations, this finding is of
interest with regard to autoantibodies to these enzymes and growth factors such as interleukin-6 (IL-6), platelet-
derived growth factor (PDGF), and tumor necrosisin lupus patients because one may envision two inter-
active models. In the first, overexpression of these pro- factor-a (TNF-a) [54–56]. These, in turn, are able to
stimulate mesangial cell proliferation [57, 58] so that theteins might provide an antigenic stimulus when nuclear
proteins are released in the course of cell necrosis or pathophysiological mechanisms are likely to evolve into
a self-perpetuating process that eventually results in in-apoptosis. In the other, the presence of circulating anti-
topoisomerase antibodies might induce an increased terstitial fibrosis. The production of signaling proteins
might be expected to go along with an increase in tran-transcription of topoisomerase mRNA via yet unex-
plained mechanisms. Finally, both mechanisms might scriptional activity and concomitant augmentation of
topoisomerase I levels. However, this did not becomecooperate in a positive feedback loop. Because both
hypotheses would directly implicate topoisomerases in apparent in our investigation, possibly because of a pre-
ponderance of other metabolic activities. In contrast,the pathogenesis of LN, we believe that this issue merits
further investigation. mesangial cell proliferation was clearly outlined by topo-
isomerase IIa expression.Another interesting aspect is the tendency toward pos-
itive correlations between the previously mentioned pa- The proliferative activity of renal interstitial cells has
been investigated in previous studies and has been foundrameters, which indicate an association between cellular
proliferation and metabolic activity on one hand and to correlate with a variety of pathological conditions [43,
59–62]. Like in our study, it emerges that the proliferat-between glomerular and tubulointerstitial pathological
processes on the other. Furthermore, their association ing cell fraction in the glomeruli is essentially represented
by mesangial cells and in the tubulointerstitium by resi-with monocytic infiltrates in the glomeruli and the tubu-
lointerstitium was of interest (Table 2). Indeed, it ap- dent fibroblasts [59]. Some investigators further sought to
assess the proliferation of monocytogenic cells by meanspears that the expression of topoisomerases correlates
with the density of Ki-M1p–positive cells in both renal of double-staining procedures. One study reported that
approximately 4% of these cells were cycling [59], whichtissue compartments, except that the tubulointerstitial
monocytic infiltrate showed no correlation with glomeru- corresponds to the average proliferative activity in mono-
cyte-rich interstitial infiltrates in the human organism (ourlar topoisomerases I and II and with tubular topoisomer-
ase I. This suggests that inflammatory responses in glo- unpublished observations). Indeed, when monocytes em-
igrate from circulating blood into the perivascular inter-meruli and in the tubulointerstitium may be uncoupled
from renal cell reactions and may represent separate, if stitium, they achieve one single-cell division before un-
dergoing terminal differentiation [63]. This explains thatnot independent, pathological processes.
These observations are nevertheless in keeping with small numbers of proliferating monocytes are usually
encountered in the vicinity of capillaries in areas of in-the putative pathophysiological mechanisms underlying
chronic renal diseases. In a first step, immune deposits flammation when large tissue sections are examined.
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However, given the low relative numbers of monocytes eration and a brisk immune reaction. Conversely, in enti-
present in the glomeruli of core biopsies from renal tis- ties with low proliferative activity and attenuated in-
sue, multiple sections would have to be scanned in order flammatory changes at the renal level, the efficacy of
to detect single proliferating cells. Results from these such drugs may be considerably impaired. Considering,
considerations show that monocyte proliferation hardly however, that many of the entities known to evolve
plays a role in the increase of renal interstitial cell num- slowly—but irremediably—displayed fairly high levels
bers, which is mainly due to proliferation of cells of of topoisomerase I, one might envisage a treatment with
fibroblastic and myofibroblastic lineage. topoisomerase I inhibitors in such conditions [71]. In
A striking observation was the consistent overall addition to a different mechanism of action that might
down-regulation of topoisomerases and the relative pau- be effective in otherwise refractory cases, these would
city of monocytic infiltrates in CTN. The pharmacologi- have the advantage of a lesser nephrotoxicity compared
cal immunosuppression in transplant patients and possi- with cyclosporine A and related drugs [72]. Similarly, the
bly its nephrotoxic side effects provide a most likely antiproliferative effect of topoisomerase IIa inhibitors
explanation for this phenomenon. Indeed, cyclosporine [73, 74] might be exploited in lesions with any amount
A and tacrolimus (FK-506) have been shown to repress of pathological proliferative activity and in particular in
mesangial cell proliferation via inhibition of thrombox- cases with resistance to corticosteroids, alkylating agents,
ane synthase and guanine depletion [64, 65], consistent or cyclosporine, among others.
with a reduced expression of topoisomerase IIa. Interest- Although our findings must be considered as prelimi-
ingly, both drugs apparently also interfere with gene nary, they show that the expression of DNA topoisomer-
transcription [66, 67], which may result in decreased cyto- ases in kidney tissue correlates with the histopathological
kine production. Although nothing appears to be known diagnosis and to some extent with clinical characteristics.
about a potential interaction of these drugs with topo- Moreover, there appears to be an association with the
isomerase I, low transcriptional activity might go along density and the distribution of monocytic infiltrates,
with a reduced topoisomerase I expression. The underly- which, in turn, exhibit distinctive patterns in different
ing mechanisms remain to be investigated. On the other entities. Assessment of these parameters might therefore
hand, it has been shown that tacrolimus efficiently inter- usefully complement current diagnostic procedures and
feres with antibody production and complement deposi- possibly allow prognostic predictions. The latter remains
tion, lymphocyte proliferation, and the accumulation of to be ascertained by clinicopathologic studies on larger
monocytes as well as their adhesion to vascular endothe- series and with long-term follow-up. Provided that a
lium by suppression of intercellular adhesion molecule-1 correlation with the clinical course can be established,
(ICAM-1) [68–70]. Although an additional anti-inflam- topoisomerase inhibitors might provide a valuable alter-
matory effect by inhibition of monocyte proliferation native to standard therapy protocols.
must not be excluded, this is probably of minor impor-
tance compared with the repression of cytokine produc- Reprint requests to Pierre Rudolph, M.D., Department of Pathology,
University of Kiel, Michaelisstr. 11, 24105 Kiel, Germany.tion. While our results clearly reflect these mechanisms,
E-mail: prudolph@path.uni-kiel.dethey also insinuate that the loss of proliferative—that
is, regenerative—potential, and the virtual extinction of
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